safusidenib

Drug identity checked against registry records

Also recorded as AB-218; DS-1001b

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

TrialSponsorPhaseStatusPrimary completion
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)NCT05303519NUVBPhase 3Recruiting2028-12-01Estimated

Regulatory dates and decisions

No regulatory events match this view.This does not mean no FDA events have occurred.